Open AccessSustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell–Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19)
Author(s) -
Jakob Malsy,
Luzia Veletzky,
Janna Heide,
Annette Hennigs,
Ines Gil-Ibanez,
Alexander Stein,
Marc Lütgehetmann,
Ulrich Rosien,
Dorothea Jasper,
Sven Peine,
Jens Hiller,
Friedrich Haag,
Stefan Schmiedel,
Samuel Huber,
Sabine Jordan,
Marylyn M. Addo,
Julian Schulze zur Wiesch
Publication year - 2020
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciaa1637
Subject(s) - convalescent plasma , covid-19 , medicine , coronavirus , virology , betacoronavirus , coronavirus infections , disease , immunology , infectious disease (medical specialty) , outbreak
We provide detailed clinical, virological, and immunological data of a B-cell–depleted patient treated with obinutuzumab for follicular lymphoma with protracted coronavirus disease 2019 (COVID-19) and viremia. A sustained response was achieved after 2 courses of remdesivir and subsequent convalescent plasma therapy. Immunocompromised patients might require combined and prolonged antiviral treatment regimens.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom